Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
205 hedge funds and large institutions have $2.58B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2023 Q1 according to their latest regulatory filings, with 63 funds opening new positions, 47 increasing their positions, 65 reducing their positions, and 26 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 3 → 9 (+6)
142% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 26
127% more capital invested
Capital invested by funds: $1.14B → $2.58B (+$1.44B)
101% more call options, than puts
Call options by funds: $222M | Put options by funds: $110M
22% more funds holding
Funds holding: 168 → 205 (+37)
28% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 65
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$127M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$42.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$21.4M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$20.4M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$18.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FAM
Fred Alger Management
New York
|
-$78.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$49.1M |
| 3 |
Millennium Management
New York
|
-$32.2M |
| 4 |
Morgan Stanley
New York
|
-$28.8M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$27.9M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OLVIG
226
Oliver Lagore Vanvalin Investment Group
Flint,
Michigan
| – | -$4.07K | -107 | Closed |
|
|
AF
227
Affiance Financial
St. Louis Park,
Minnesota
| – | -$3.8K | -100 | Closed |
|
|
BAAM
228
Baker Avenue Asset Management
San Francisco,
California
| – | -$950 | -25 | Closed |
|
|
CS
229
Comerica Securities
Detroit,
Michigan
| – | -$570 | -15 | Closed |
|
230
Balyasny Asset Management
Chicago,
Illinois
| – | -$418 | -11 | Closed |
|
RETA Hedge Fund Activity: Q1 2023 in Review
205 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q1 2023, worth a combined $2.58B — up 127% from $1.14B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new RETA positions and 26 closed out — a net gain of 37 holders — while 47 added to existing stakes and 65 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $127M. The largest seller was Fred Alger Management, cutting an estimated $78.3M.
- 205 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q1 2023, up from 168 in Q4 2022.
- Funds reported $2.58B of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q1 2023, up 127% quarter-over-quarter.
- 63 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q1 2023 and 26 closed out, a net change of +37 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q1 2023 was Perceptive Advisors, an estimated $127M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q1 2023 was Fred Alger Management, an estimated $78.3M sold.
Based on aggregated 13F filings for Q1 2023.